Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, raised $108 million by offering 7.5 million ADSs at $14.40, the midpoint of the revised range of $13.40 to $15.40. The company originally planned to offer the same number of ADSs at the as-converted last close of its shares on the Euronext Paris (IVA), but added a range on Wednesday. At pricing, the company commands a fully diluted market cap of $559 million.
Inventiva plans to list on the Nasdaq under the symbol IVA. Jefferies, Stifel, and Guggenheim Securities acted as lead managers on the deal.
